Lung Disease Clinical Trial
Official title:
Comparative Study of the Non-dependent Continuous Positive Airway Pressure and High-frequency Positive-pressure Ventilation on Fluid Responsiveness During One-lung Ventilation for Thoracoscopic Surgery
The stroke volume variation (SVV), measured using the Vigileo-FloTrac system (Edwards
Lifescience, Irvine, CA), has been shown to able to predict fluid responsiveness during
one-lung ventilation (OLV) in patients undergoing pulmonary lobectomy (sensitivity: 82.4%,
specificity: 92.3%).1 Many parameters such as tidal volume (TV),1-2 positive end-expiratory
pressure (PEEP),3 respiratory rate (RR), 4 chest and lung compliance,5 heart rate and rhythm,
and ventricular function and afterload,6-7 all have been documented to have effects on the
SVV.
SVV is calculated as the variation of beat-to-beat SV from the mean value during the most
recent 20 seconds of data: SVV = (SVmax − SVmin)/SVmean, where SVmax, SVmin, and SVmean are,
respectively, the maximum, minimum, and mean SV determined by the system.
SVV may not be sufficiently sensitive to predict fluid responsiveness in patients with right
ventricular (RV) dysfunction due to concomitant increases in RV afterload, that lead to a
decrease in preload variation and subsequent inaccuracy in SVV measurements.8
OLV may increase airway pressure, resulting in increases in the RV afterload, end-diastolic
volume, and stroke work index, thus impeding RV function.9-11The increases in the right
ventricular afterload may exaggerate the cyclic variation in stroke volume.12
In the authors' previous study,9 they found that the high-frequency positive-pressure
ventilation (HFPPV) was superior to continuous positive-airway pressure (CPAP) for OLV,
resulting in significantly higher RV ejection fraction, lower RV afterload and higher
arterial oxygenation, whereas the former limiting the adequate operative field visualization
during video-assisted thoracoscopic surgery (VATS).13
The effects of the nondependent lung ventilation with HFPPV and CPAP on the SVV and fluid
responsiveness during OLV has not yet been studied.
In all patients, standard monitors, and state and response entropy (SE and RE, respectively)
based-depth of anesthesia will be applied. Normothermia will be maintained by using
forced-air warming blankets. Anesthetic technique will be standardized in all studied
patients. Anesthesiologists who give the anesthetic will be not involved in the collection of
outcome data. General anesthesia will be induced with propofol (2-3 mg kg-1) and fentanyl
(2-3 µg kg-1) to achieve a SE value less than 50 and the difference between RE and SE less
than 10.
Cisatracurium (0.2mg kg-1) will be administered to facilitate the placement of a left-sided
double-lumen tube, and the correct position of its tip will be confirmed with a fiberoptic
bronchoscope.
Anesthesia will be maintained with 0.7 to 1.5 minimum alveolar concentration of sevoflurane
and 0.5 µg kg-1 increments of fentanyl to maintain the SE values less than 50 and the
difference between RE and SE less than 10. Suppression of the second twitch in train-of-four
stimulation of the ulnar nerve will be maintained with 0.03mg kg-1 increments of
cisatracurium.
The radial artery will be catheterized. Cardiac index (CI) and SVV will be measured by using
a Vigileo-FloTrac system (v1.14, Edwards Lifescience, Irvine, CA).
Patients' two lungs (TLV) will be mechanically ventilated with a pressure-controlled
ventilation mode, a fraction of inspired oxygen (FiO2) of 0.4 in air, TV of 8 mL kg-1
(predicted body weight (PBW)), inspiratory to expiratory (I: E) ratio of 1:2.5 and PEEP of 5
cm H2O, fresh gas flow (FGF) of 1.5-1.7 L min-1, and RR adjusted to achieve a PaCO2 of 35-45
mm Hg.
During OLV,TV, FiO2, I: E ratio, PEEP, FGF, and RR, will be maintained as during TLV and the
lumen of the nondependent lung will be left open to air.
After thoracostomy, patients will be randomly allocated to one of two by drawing sequentially
numbered sealed opaque envelopes containing a computer-generated randomization code.
The patient's nondependent lung during OLV will be ventilated with a CPAP of 2 cm H2O or
HFPPV as randomized.
All patients will receive lactated Ringer's solution at 2mL kg-1 h-1 during surgery. The
capability of SVV to predict fluid responsiveness during CPAP or HFPPV will be assessed at 30
min after randomization.
Hemodynamic control will be standardized according to the authors' protocol. If MAP dropped
down to 60 mmHg, 250 mL of plasma protein fraction 5% will be administered, and, if this will
not enough, repeated doses of intravenous of ephedrine 5 mg or phenylephrine 100 µg, will be
administered to maintain urine output to be equal or greater than 0.5 mL kg-1 hour-1. A
hemoglobin concentration of 8 g dL-1 or greater will be compensated with red blood cell
concentrates.
An independent investigator blinded to the study groups who will not be involved in the
patients' management collected the data.
As in previous studies,14-15 the sample size is determined by considering that an area under
the ROC curve ≥ 0.8 is clinically reliable to predict fluid responsiveness. To detect a 0.3
difference from the null hypothesis of 0.5, 28 patients will be required in each group with a
type-I error of 0.05 and a power of 80% under the ROC curve, assuming equal number of
responders and non-responders. To compensate for a dropout rate of 10%, 31 patients will be
included in each group.
Normal distributions of data will be assessed using Kolmogorov-Smirnov test. Student's paired
t-test or the Wilcoxon signed-rank test will be used to compare hemodynamic variables
obtained at the 2 time points (T0, T1) before and after volume expansion. Hemodynamic
variables between responders and non-responders within the group at each time point will be
compared using Student independent t-test or Mann-Whitney U-test where appropriate. The x2
test will be used when indicated. The Pearson rank method tests linear correlations between
SVV before volume loading (T0) and absolute changes in SVV (∆SVV) and percentage change in
SVI (∆SVI) after volume. The responders are defined as those patients who demonstrates a ≥
15% increase in CI after volume expansion between T0 and T1.16 A ROC curve for each variable
will be generated and an area under the ROC curve will be calculated. Using this analysis,
the optimal threshold value, sensitivity and specificity of SVV during each study
intervention could be determined. The ROC curves will be compared using the DeLong test. Data
will be expressed as mean ± SD, medians [IQR], or number (%). A value of p< 0.05 is
considered to be statistically significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02217423 -
Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Completed |
NCT01679301 -
Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator
|
N/A | |
Terminated |
NCT00966823 -
Fetal Tracheal Balloon Study in Diaphragmatic Hernia
|
Phase 2 | |
Completed |
NCT00139152 -
Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair
|
Phase 4 | |
Completed |
NCT00052052 -
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Completed |
NCT00013949 -
Cardiovascular Vulnerability to Particulate Exposure
|
N/A | |
Recruiting |
NCT02963467 -
Effect of Smoking on Ventilation-Perfusion Ratio
|
N/A | |
Recruiting |
NCT02965300 -
The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis
|
N/A | |
Enrolling by invitation |
NCT02946658 -
Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders
|
Phase 1/Phase 2 | |
Recruiting |
NCT02913365 -
Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
|
N/A | |
Completed |
NCT01735526 -
Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation
|
N/A | |
Completed |
NCT01952002 -
Clinical Safety for the Inspiratory Muscle Training
|
N/A | |
Recruiting |
NCT01450644 -
Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease
|
Phase 2 | |
Completed |
NCT01215279 -
AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
|
Phase 2 | |
Completed |
NCT01153321 -
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Completed |
NCT00837681 -
Pulmonary Complications of Hematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02055222 -
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
|
||
Completed |
NCT01222442 -
To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart
|
Phase 1 |